What’s the Difference Between Fast Track & Breakthrough Therapy Designations?
April 20th, 2020
The Food and Drug Administration (FDA) granted Breakthrough Therapy status to COMPASS Pathway’s clinical trials evaluating psilocybin for the treatment of severe treatment-resistant depression. Shortly after, the regulatory agency granted the same designation for the Usona Institute’s psychedelic therapy targeting major depressive disorder.
Let’s take a look at what the Breakthrough Therapy status means and how it compares to the FDA’s other expedited review programs that accelerate drug approvals.
Expedited Review Programs
The Food and Drug Administration (FDA) attempts to review all drugs in a timely manner, but they prioritize therapies that treat serious of life-threatening diseases or have the potential to provide unusually large benefits to patients. The goal is to maximize the use of its resources in a way that promotes health and safety among patients.
There are four different expedited review programs available to companies that meet these criteria:
- Priority Review – Requested alongside a new drug application (NDA) or biologics license application (BLA) to cut a drug’s FDA review period from ten months to six months.
- Fast Track – Requested as early as the investigational new drug (IND) application to provide extra opportunities to meet with the FDA, discuss study design, and identify the most efficient pathways to approval.
- Breakthrough Therapy – Requested as early as the investigational new drug (IND) application to provide enhanced Fast Track benefits, as well as potentially skip portions of the standard FDA review process.
- Accelerated Approval – Requested at any stage for drugs with long-term endpoints (e.g. increased survival) to permit approvals based on surrogate endpoints that are more easily measured and reasonably likely to improve outcomes.
In addition, the FDA may provide a priority review voucher to companies that are developing drugs that are not profitable but have a significant impact on patients’ quality of life. These vouchers can be used on future drugs that have wider indicators, although companies must pay a nominal ~$3 million fee in order to use the voucher.
Implications for Investors
The FDA’s expedited review process shortens the development timeline for clinical trials and could eliminate some of the more costly requirements and risks. However, the designation doesn’t guarantee a successful clinical trial or that a drug will be brought to market in a timely fashion — that still depends on the company and drug’s efficacy.
According to at least one study, the FDA’s decision to Fast Track drug candidates leads to an increase in a public company’s value. The study found abnormal trading volume and excess daily stock returns, along with greater institutional ownership and analyst attention among companies that were granted the Fast Track status.
Investors should understand the differences between different FDA expedited review processes before investing in psychedelic stocks or other areas of the market. By understanding these differences, they can improve the risk/reward profile of their investment holdings.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.